Stockpolly
Search
Delisting risk
APM · NASDAQ · Biotechnology

Aptorum Group (APM)

Developing oncology, infectious disease, and diagnostic assets for unmet medical needs.

$8.26
At close−1.44 (−14.84%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025Q2 FY26Jun 2026
Revenue111110000100
Cost of revenue111111000000
Gross profit−1−1−1−1−1−1000100
1199896421611
Research & development755443320300
444443111310
Selling & marketing−30−20−20000000
General & administrative706060000010
Other expenses000000−100000
Operating income−12−9−10−8−9−7−4−3−1−5−11
24−80600600000
Interest income000000000000
Interest expense−3,6990−3,699000000000
Other non-operating income1470−600−600000
Income before tax12−17−10−3−9−72−3−1−5−10
Income tax expense000000000000
Net income from continuing operations12−17−10−3−9−72−3−1−5−11
Other adjustments011111000000
Net income13−16−9−2−8−53−3−2−5−12
EPS, basic$3.90−$4.69−$2.52−$0.53−$2.22−$1.43$5.10−$5.00−$2.90−$0.62−$1.30−$0.30
EPS, diluted$3.90−$4.69−$2.52−$0.53−$2.22−$1.43$5.10−$5.00−$2.90−$0.62−$1.30−$0.30
Weighted average shares, basic334444111111
Weighted average shares, diluted334444111111
EBITDA13−16−9−2−8−63−2−1−5−11
Depreciation & amortization111111000000
EBIT12−17−10−3−9−72−3−1−5−10